Skip to main content
PMC home page
Annals of the Rheumatic Diseases logoLink to Annals of the Rheumatic Diseases
. 1968 Nov;27(6):582–589. doi: 10.1136/ard.27.6.582

The lymphocyte transformation test and gold hypersensitivity.

E J Denman, A M Denman
PMCID: PMC1010479  PMID: 5728102

Full text

PDF
582

Images in this article

583Image
on p.583

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. DENMAN A. M., HUBER H., WOOD P. H., SCOTT J. T. RETICULOCYTE COUNT IN PATIENTS WITH RHEUMATOID ARTHRITIS, WITH OBSERVATIONS ON THE EFFECT OF GOLD THERAPY ON BONE MARROW FUNCTION. Ann Rheum Dis. 1965 May;24:278–284. doi: 10.1136/ard.24.3.278. [DOI] [PMC free article] [PubMed] [Google Scholar]
  2. EDSTROM G. Value and complications of gold therapy in rheumatoid arthritis. Acta Rheumatol Scand. 1959;5(1):53–58. [PubMed] [Google Scholar]
  3. LEONARD J. C. Toxic effects of phenylbutazone with special reference to disorders of the blood. Br Med J. 1953 Jun 13;1(4823):1311–1313. doi: 10.1136/bmj.1.4823.1311. [DOI] [PMC free article] [PubMed] [Google Scholar]
  4. Loewi G., Temple A., Vischer T. L. The immunological significance in the guinea-pig of in vitro transformation of lymph node, spleen and peripheral blood lymphocytes. Immunology. 1968 Feb;14(2):257–264. [PMC free article] [PubMed] [Google Scholar]
  5. MCCARTHY D. D., CHALMERS T. M. HEMATOLOGICAL COMPLICATIONS OF PHENYLBUTAZONE THERAPY: REVIEW OF THE LITERATURE AND REPORT OF TWO CASES. Can Med Assoc J. 1964 May 2;90:1061–1067. [PMC free article] [PubMed] [Google Scholar]
  6. Persellin R. H., Hess E. V., Ziff M. Effect of a gold salt on the immune response. Arthritis Rheum. 1967 Apr;10(2):99–106. doi: 10.1002/art.1780100204. [DOI] [PubMed] [Google Scholar]
  7. ROBBINS J. H. TISSUE CULTURE STUDIES OF THE HUMAN LYMPHOCYTE. Science. 1964 Dec 25;146(3652):1648–1654. doi: 10.1126/science.146.3652.1648. [DOI] [PubMed] [Google Scholar]
  8. Saphir J. R., Ney R. G. Delayed thrombocytopenic purpura after diminutive gold therapy. JAMA. 1966 Feb 28;195(9):782–784. [PubMed] [Google Scholar]
  9. Sarkany I. Lymphocyte transformation in drug hypersensitivity. Lancet. 1967 Apr 8;1(7493):743–745. doi: 10.1016/s0140-6736(67)91362-1. [DOI] [PubMed] [Google Scholar]
  10. TULLIS J. L. Prevalence, nature and identification of leukocyte antibodies. N Engl J Med. 1958 Mar 20;258(12):569–578. doi: 10.1056/NEJM195803202581201. [DOI] [PubMed] [Google Scholar]
  11. Vischer T. L. Lymphocyte cultures in drug hypersensitivity. Lancet. 1966 Aug 27;2(7461):467–469. doi: 10.1016/s0140-6736(66)92773-5. [DOI] [PubMed] [Google Scholar]
  12. Vischer T. L., Stastny P. Time of appearance and distribution of cells capable of secondary immune response following primary immunization. Immunology. 1967 Jun;12(6):675–687. [PMC free article] [PubMed] [Google Scholar]
  13. WEISSMANN G., XEFTERIS E. D. Phenylbutazone leukopenia. AMA Arch Intern Med. 1959 Jun;103(6):957–961. doi: 10.1001/archinte.1959.00270060109014. [DOI] [PubMed] [Google Scholar]

Articles from Annals of the Rheumatic Diseases are provided here courtesy of BMJ Publishing Group

RESOURCES